Filing Details

Accession Number:
0001209191-11-049252
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-09-28 13:58:33
Reporting Period:
2011-09-26
Filing Date:
2011-09-28
Accepted Time:
2011-09-28 13:58:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1135906 Zalicus Inc. ZLCS Pharmaceutical Preparations (2834) 043514457
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1134655 Ansbert Gadicke C/O Mpm Asset Management
200 Clarendon St., 54Th Floor
Boston MA 02116
No No Yes No
1134657 Luke Evnin C/O Mpm Asset Management
200 Clarendon St., 54Th Floor
Boston MA 02116
No No Yes No
1166285 Michael Steinmetz C/O Mpm Asset Management
200 Clarendon St., 54Th Floor
Boston MA 02116
No No Yes No
1221595 Iii J Nicholas Simon C/O Mpm Asset Management
200 Clarendon St., 54Th Floor
Boston MA 02116
No No Yes No
1249153 Dennis Henner C/O Mpm Asset Management
200 Clarendon St., 54Th Floor
Boston MA 02116
No No Yes No
1252522 Nicholas Galakatos C/O Mpm Asset Management
200 Clarendon St., 54Th Floor
Boston MA 02116
No No Yes No
1252525 Kurt Wheeler C/O Mpm Asset Management
200 Clarendon St., 54Th Floor
Boston MA 02116
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2011-09-26 210,000 $1.11 14,423,961 No 4 S Indirect See Footnote
Common Stock Disposition 2011-09-27 200,000 $1.09 14,223,961 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Footnotes
  1. The shares were sold as follows: 174,808 by MPM BioVentures III-QP, L.P. ("BV III QP"), 11,754 by MPM BioVentures III, L.P. ("BV III"), 3,385 by MPM Asset Management Investors 2003 BVIII LLC ("AM 2003"), 5,279 by MPM BioVentures III Parallel Fund, L.P. ("BV Parallel") and 14,774 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV KG").
  2. Represents weighted average sales price. The shares were sold at prices ranging from $1.07 to $1.16. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  3. The shares are held as follows: 11,946,398 by BV III QP, 802,078 by BV III, 230,999 by AM 2003, 359,799 by BV Parallel, 1,008,372 by BV KG and 76,315 by MPM Asset Management LLC ("MPM AM"). MPM BioVentures III GP, L.P. ("MPM III GP") and MPM BioVentures III LLC ("MPM III LLC") are the direct and indirect general partners of BV III QP, BV III and BV Parallel and BV KG. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz and Kurt Wheeler are the members of MPM III LLC and AM 2003. Luke Evnin and Ansbert Gadicke are members of MPM AM. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein.
  4. The shares were sold as follows: 166,485 by BV III QP, 11,194 by BV III, 3,223 by AM 2003, 5,028 by BV Parallel and 14,070 by BV KG.
  5. Represents weighted average sales price. The shares were sold at prices ranging from $1.01 to $1.13. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  6. The shares are held as follows: 11,779,913 by BV III QP, 790,884 by BV III, 227,776 by AM 2003, 354,771 by BV Parallel, 994,302 by BV KG and 76,315 by MPM AM. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein.